BBIBP‐CorV – Sinopharm‐Beijing vs placebo
Confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted1 study · 25435 participantsHigh
The review found no eligible studies for this question.
The review found no eligible studies for this question.
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in systemic reactogenicity eventse compared with placebo (moderate certainty).
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).